Article Text

Download PDFPDF
Advanced clinical trials of dendritic cell vaccines in ovarian cancer
  1. Quan Guo1,
  2. Qing Yang1,
  3. Jun Li1,
  4. Guipeng Liu1,
  5. Igor Nikoulin2,
  6. Steve Jia3
  1. 1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China
  2. 2Research and Development, IriSys, LLC, San Diego, California, USA
  3. 3RD Center, Pacificbio Inc, Irvine, California, USA
  1. Correspondence to Dr Quan Guo, Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China; guoq{at}


Epithelial ovarian cancer (EOC) is the most common and leading cause of death for gynecologic cancer in the western world. Current standard treatments with limited selection of chemotherapies cannot meet patients’ urgent needs. Immunotherapies have recently demonstrated clinical benefits in a variety of solid tumors and may offer a promising frontier for treating EOC. Dendritic cells (DCs) are key coordinators of the innate and adaptive immune system in induction of antitumor immunity. DC-based vaccinations showed clinical benefits and encouraging safety profiles in a few phase II clinical trials for patients with EOC and currently are in a phase III double-blind, randomized, placebo-controlled clinical trial. In this review, we have searched Pubmed and Clinicaltrials. gov databases for past and current phase II or phase III clinical trials with focus on EOC and DC vaccines. Outcomes and implications of the completed and ongoing trials are discussed.

  • ovarian neoplasms
  • vaccination
  • immunotherapy, adoptive
View Full Text

Statistics from


  • Contributors QG and SJ developed the review concept and structure. All authors reviewed the literature, wrote and edited the manuscript and approved the final version.

  • Funding This work was supported by a grant from the National Natural Science Foundation of China (No. 81872125).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.